Compounding pharmacy regulations: experience of the North American pharmaceutical market

In order to improve regulation of socially significant type of activity in the field of compounding pharmacy production, the review summarizes the technological, organizational and regulatory requirements for ensuring quality and safety of compounding drugs, as well as historical and technical analysis of the compounding pharmacy regulation in North American pharmaceutical market. The main imperatives are identified and the best practices recommended for implementation into the current state of the pharmaceutical market in the Russian Federation. 

1. Global Market Insights. Compounding Pharmacies Market 2022. Available at: https://www.gminsights.com/industry-analysis/compounding-pharmacies-market (accessed 28.09.2022).

2. U.S. Food and Drug Administration Section 503A of the Federal Food, Drug, and Cosmetic Act. Available at: https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act (accessed 28.09.2022).

3. Barlas S. Two draft FDA guidance documents stir controversy. PT. 2015; 40 (9): 569.

4. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee. Federal Register Vol. 79, No. 8. Available at: http://www.gpo.gov/fdsys/pkg/FR-2014-01-13/pdf/2014-00322.pdf (accessed 28.09.2022).

5. Bonner L. FDA continues to release compounding guidance. Pharmacy Today. 2015; 21 (3): 78.

6. Teshome B.F., Reveles K.R., Lee G.C., et al. How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak. J Am Pharm Assoc. 2014; 54 (4): 441–5. https://doi.org/10.1331/JAPhA.2014.14011.

7. Higby G.J. The continuing evolution of American pharmacy practice, 1952–2002. J Am Pharm Assoc. 2002; 42 (1): 12–5. https://doi.org/10.1331/108658002763538017.

8. Nolan A. Federal authority to regulate the compounding of human drugs. CRS Report for Congress, 2013. Available at: https://sgp.fas.org/crs/misc/R43038.pdf (accessed 28.09.2022).

9. Boodoo J.M. Compounding problems and compounding confusion: federal regulation of compounded drug products and the FDAMA circuit split. Am J Law Med. 2010; 36 (1): 221–48.

10. Watson C.J., Whitledge J.D., Siani A.M., Burns M.M. Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors. J Med Toxicol. 2021; 17 (2): 197–217. https://doi.org/10.1007/s13181-020-00814-3.